England - London • Corporate and commercial

Covington & Burling LLP

We only have limited information for this firm. Consider the following firms which have provided more information:

With strong capabilities in both US and UK law, the ‘very commercial and extremely responsive’ corporate team at Covington & Burling LLP is well-regarded for its capabilities across energy, technology, pharmaceuticals, and life sciences M&A. The team is led by Gregor Frizzell, who regularly handles strategic collaborations, venture capital transactions and cross-border M&A. The ’exceptional’ Louise Nash counsels multinational companies on acquisitions, divestitures, joint ventures and licensing transactions. Other key names include managing partner James Halstead, who focuses on transactions relating to new technologies, complex M&A and fundraisings, as well as Paul Claydon and James Gubbins, who specialise in M&A, IPOs and securities issues. Simon Amies left the team in May 2023 to join Cooley (UK) LLP.

Legal 500 Editorial commentary

Testimonials

Collated independently by Legal 500 research team.

  • ‘Deep knowledge of the life sciences industry.’

  • ‘Very commercial and extremely responsive.’

Abbreviated data is displayed for this firm.

Key clients

  • AbbVie, Inc.
  • Arcutis Biotherapeutics, Inc.

Abbreviated data is displayed for this firm.

Work highlights

  • Advised Arecor Therapeutics PLC, a globally focused biopharmaceutical company, in its acquisition of Tetris Pharma Limited.
  • Advised GammaDelta Therapeutics Ltd on its sale to Takeda Pharmaceutical Company.

Abbreviated data is displayed for this firm.